Market news

Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency programMALVERN, Pa., Aug. 31, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that Roberto Cuca, Chief Operating Officer and Chief Financial Officer, will step down from the role effective today. “On behalf of the Board and management team, I woul

Detailed price information for Tela Bio Inc (TELA-Q) from The Globe and Mail including charting and trades.

Despite a 4% revenue dip, TELA Bio Inc (TELA) sees strong international growth and improved gross margins while executing a cost-reduction plan to extend its cash runway.

Moby summary of TELA Bio, Inc.'s Q2 2026 earnings call

TELA Bio (TELA) delivered earnings and revenue surprises of -17.65% and -3.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

MALVERN, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Board of Directors of TELA Bio approved inducement grants of stock options to purchase an aggregate of 2,370,000 shares of its common stock and restricted stock units covering 500,000 shares of its common stock to the Company’s newly-hired Chief Executive Officer, He

Detailed price information for Tela Bio Inc (TELA-Q) from The Globe and Mail including charting and trades.

MALVERN, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, announced that the Board of Directors (the “Board”) has appointed Heather Getz as Chief Executive Officer and Director, effective today. “As TELA Bio enters its next phase of growth and commercial execution, the Board is pleased to welcome Heather as our next Chief Executive Officer,” said

MALVERN, Pa., July 29, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 46th Annual Growth Conference. TELA’s management is scheduled to present at the Canaccord Genuity 46th Annual Growth Conference at 8:30 am ET on August 12th, 2026. Interested parties can access the live and archived w

MALVERN, Pa., July 20, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2026 financial results on Monday, August 10, 2026. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Second Quarter Earnings Confe